REPORT FROM THE AHA/ASA INTERNATIONAL STROKE CONFERENCE – Patients who do not respond to low-dose acetylsalicylic acid (ASA) for secondary stroke prevention are unlikely to respond to a higher dose, according to researchers at the University of Buffalo, NY (Gengo et al. Abstract 85).